MENU
+Compare
PULM
Stock ticker: NASDAQ
AS OF
Aug 15 closing price
Price
$4.71
Change
-$0.31 (-6.18%)
Capitalization
17.2M

PULM Pulmatrix Forecast, Technical & Fundamental Analysis

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE... Show more

Industry: #Biotechnology
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PULM with price predictions
Aug 15, 2025

PULM's Indicator enters downward trend

The Aroon Indicator for PULM entered a downward trend on August 15, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 287 similar instances where the Aroon Indicator formed such a pattern. In of the 287 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PULM turned negative on August 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PULM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PULM's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PULM advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

PULM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.069) is normal, around the industry mean (19.407). P/E Ratio (0.000) is within average values for comparable stocks, (50.758). PULM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.852). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (46.512) is also within normal values, averaging (299.803).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PULM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PULM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PULM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals for pulmonary disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
36 Crosby Drive
Phone
+1 781 357-2333
Employees
22
Web
https://www.pulmatrix.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FOSL3.100.75
+31.91%
Fossil Group
KC13.580.32
+2.41%
Kingsoft Cloud Holdings Limited
GIGM1.510.01
+0.87%
GigaMedia Limited
HIPO30.80-0.11
-0.36%
Hippo Holdings
XYL140.81-1.03
-0.73%
Xylem

PULM and Stocks

Correlation & Price change

A.I.dvisor tells us that PULM and INM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PULM and INM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PULM
1D Price
Change %
PULM100%
-6.18%
INM - PULM
29%
Poorly correlated
-0.85%
CRIS - PULM
24%
Poorly correlated
+8.93%
CERO - PULM
23%
Poorly correlated
-1.36%
MESO - PULM
23%
Poorly correlated
+2.46%
MOLN - PULM
23%
Poorly correlated
-1.42%
More